Cancer Research Audrey Hepburn Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mortarini, R.
Right arrow Articles by Anichini, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mortarini, R.
Right arrow Articles by Anichini, A.
[Cancer Research 63, 2535-2545, May 15, 2003]
© 2003 American Association for Cancer Research

Immunology

Lack of Terminally Differentiated Tumor-specific CD8+ T Cells at Tumor Site in Spite of Antitumor Immunity to Self-Antigens in Human Metastatic Melanoma1

Roberta Mortarini, Adriano Piris, Andrea Maurichi, Alessandra Molla, Ilaria Bersani, Aldo Bono, Cesare Bartoli, Mario Santinami, Claudia Lombardo, Fernando Ravagnani, Natale Cascinelli, Giorgio Parmiani and Andrea Anichini2

Human Tumors Immunobiology [R. M., A. Mo., I. B., A. A.] and Tumor Immunotherapy [G. P.] Units, Departments of Pathology [A. P., C. L., F. R.], Surgery [A. B., C. B., A. Ma., M. S.] and Scientific Direction [N. C.], Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, 20133, Italy

Activation of CTL-mediated antitumor immunity to self-epitopes expressed by neoplastic cells is thought to be prevented, at any stage of tumor progression, by tolerance mechanisms. In contrast, in 74 American Joint Committee on Cancer stages I-IV melanoma patients, we found that development of lymph node metastases is a key event triggering CD8+ T-cell-mediated immunity to self-epitopes encoded by melanocyte differentiation antigens. This was shown by the increased peripheral precursor frequency to Melan-A/Mart-1, gp100, and tyrosinase epitopes in stage III and IV compared with stage I and II patients, and by accumulation of functional memory T cells directed to Melan-A/Mart-126–35 in tumor-invaded lymph nodes. However, in tumor-invaded lymph nodes of most patients, CD8+ T cells directed to melanocyte differentiation antigens or to tumor-restricted antigens (MAGE-3 and NY-ESO-1 epitopes), showed a CCR7+ CD45RA+ CD27+ CD28+ perforin- "precursor" phenotype. Only in 7 of 23 cases antigen-specific CD8+ T cells in invaded lymph nodes showed a predominant CCR7- CD45RA- CD27+ CD28- perforin+ "preterminally differentiated" phenotype. In the latter subset of patients, by immunohistochemistry in lymph node lesions, we found that CD8+ T lymphocytes intermingling with the neoplastic tissue expressed a CCR7- CD45RO+/RA- phenotype, whereas CD4+ lymphocytes did not infiltrate the tumor. Furthermore, perforin and granzyme B were expressed on a higher fraction of the CD8+ cells surrounding the invading tumor compared with the lymphocytes infiltrating the neoplastic tissue. In addition, no evidence for tumor regression was found in such metastatic lesions, as documented by absence of neoplastic cell necrosis or apoptosis. These data indicate that neoplastic cells in the lymph nodes and/or increased tumor burden in metastatic disease activate CD8+ T-cell-mediated antitumor immunity to self-epitopes. However, the paucity of terminally differentiated CD8+ T cells at tumor site suggests that immunotherapy strategies may require not only the boosting of tumor immunity, but also effective means to promote CD8+ T-cell differentiation in the neoplastic tissue.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
S. Attig, J. Hennenlotter, G. Pawelec, G. Klein, S. D. Koch, H. Pircher, S. Feyerabend, D. Wernet, A. Stenzl, H.-G. Rammensee, et al.
Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas
Cancer Res., November 1, 2009; 69(21): 8412 - 8419.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Mortarini, C. Vegetti, A. Molla, F. Arienti, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, and A. Anichini
Impaired STAT Phosphorylation in T Cells from Melanoma Patients in Response to IL-2: Association with Clinical Stage
Clin. Cancer Res., June 15, 2009; 15(12): 4085 - 4094.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Harlin, Y. Meng, A. C. Peterson, Y. Zha, M. Tretiakova, C. Slingluff, M. McKee, and T. F. Gajewski
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment
Cancer Res., April 1, 2009; 69(7): 3077 - 3085.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
J. G. Casado, O. DelaRosa, G. Pawelec, E. Peralbo, E. Duran, F. Barahona, R. Solana, and R. Tarazona
Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells
Int. Immunol., January 1, 2009; 21(1): 53 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. Mazzocchi, F. Arienti, et al.
Induction of Both CD8+ and CD4+ T-Cell-Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1
Clin. Cancer Res., November 15, 2008; 14(22): 7292 - 7303.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
E. B. Walker, D. Haley, U. Petrausch, K. Floyd, W. Miller, N. Sanjuan, G. Alvord, B. A. Fox, and W. J. Urba
Phenotype and Functional Characterization of Long-term gp100-Specific Memory CD8+ T Cells in Disease-Free Melanoma Patients Before and After Boosting Immunization
Clin. Cancer Res., August 15, 2008; 14(16): 5270 - 5283.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
P. A. Savage, K. Vosseller, C. Kang, K. Larimore, E. Riedel, K. Wojnoonski, A. A. Jungbluth, and J. P. Allison
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8+ T Lymphocytes
Science, January 11, 2008; 319(5860): 215 - 220.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Lengagne, S. Graff-Dubois, M. Garcette, L. Renia, M. Kato, J.-G. Guillet, V. H. Engelhard, M.-F. Avril, J.-P. Abastado, and A. Prevost-Blondel
Distinct Role for CD8 T Cells toward Cutaneous Tumors and Visceral Metastases
J. Immunol., January 1, 2008; 180(1): 130 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani
NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients
Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Inokuma, C. dela Rosa, C. Schmitt, P. Haaland, J. Siebert, D. Petry, M. Tang, M. A. Suni, S. A. Ghanekar, D. Gladding, et al.
Functional T Cell Responses to Tumor Antigens in Breast Cancer Patients Have a Distinct Phenotype and Cytokine Signature
J. Immunol., August 15, 2007; 179(4): 2627 - 2633.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. M. Curtsinger, M. Y. Gerner, D. C. Lins, and M. F. Mescher
Signal 3 Availability Limits the CD8 T Cell Response to a Solid Tumor
J. Immunol., June 1, 2007; 178(11): 6752 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. M. Pupa, S. Giuffre, F. Castiglioni, L. Bertola, M. Cantu, I. Bongarzone, P. Baldassari, R. Mortarini, W. S. Argraves, A. Anichini, et al.
Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1
Cancer Res., May 1, 2007; 67(9): 4271 - 4277.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Parmiani, A. De Filippo, L. Novellino, and C. Castelli
Unique Human Tumor Antigens: Immunobiology and Use in Clinical Trials
J. Immunol., February 15, 2007; 178(4): 1975 - 1979.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
G. Bioley, C. Jandus, S. Tuyaerts, D. Rimoldi, W. W. Kwok, D. E. Speiser, J.-M. Tiercy, K. Thielemans, J.-C. Cerottini, and P. Romero
Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers
J. Immunol., November 15, 2006; 177(10): 6769 - 6779.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. A. Doyle, J. Zhou, M. J. Wolff, B. P. Harvey, R. M. Roman, R. J. Gee, R. A. Koski, and M. J. Mamula
Isoaspartyl Post-translational Modification Triggers Anti-tumor T and B Lymphocyte Immunity
J. Biol. Chem., October 27, 2006; 281(43): 32676 - 32683.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
I. E. Brown, C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski
Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection
J. Immunol., October 1, 2006; 177(7): 4521 - 4529.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
V. Appay, C. Jandus, V. Voelter, S. Reynard, S. E. Coupland, D. Rimoldi, D. Lienard, P. Guillaume, A. M. Krieg, J.-C. Cerottini, et al.
New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site
J. Immunol., August 1, 2006; 177(3): 1670 - 1678.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Anichini, R. Mortarini, D. Nonaka, A. Molla, C. Vegetti, E. Montaldi, X. Wang, and S. Ferrone
Association of Antigen-Processing Machinery and HLA Antigen Phenotype of Melanoma Cells with Survival in American Joint Committee on Cancer Stage III and IV Melanoma Patients.
Cancer Res., June 15, 2006; 66(12): 6405 - 6411.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J.C.L.M. Vuylsteke, B. G. Molenkamp, P. A.M. van Leeuwen, S. Meijer, P. G.J.T.B. Wijnands, J. B.A.G. Haanen, R. J. Scheper, and T. D. de Gruijl
Tumor-Specific CD8+ T Cell Reactivity in the Sentinel Lymph Node of GM-CSF-Treated Stage I Melanoma Patients is Associated with High Myeloid Dendritic Cell Content.
Clin. Cancer Res., May 1, 2006; 12(9): 2826 - 2833.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. F. Gajewski
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
Clin. Cancer Res., April 1, 2006; 12(7): 2326s - 2330s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
U. Keilholz, P. Martus, and C. Scheibenbogen
Immune monitoring of T-cell responses in cancer vaccine development.
Clin. Cancer Res., April 1, 2006; 12(7): 2346s - 2352s.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. Liu, S. A. Caldwell, K. M. Greeneltch, D. Yang, and S. I. Abrams
CTL Adoptive Immunotherapy Concurrently Mediates Tumor Regression and Tumor Escape
J. Immunol., March 15, 2006; 176(6): 3374 - 3382.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Gillmore, S.-A. Xue, A. Holler, J. Kaeda, D. Hadjiminas, V. Healy, R. Dina, S. C. Parry, I. Bellantuono, Y. Ghani, et al.
Detection of Wilms' Tumor Antigen-Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer
Clin. Cancer Res., January 1, 2006; 12(1): 34 - 42.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dranoff
The Therapeutic Implications of Intratumoral Regulatory T Cells
Clin. Cancer Res., December 1, 2005; 11(23): 8226 - 8229.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Parmiani, C. Castelli, and L. Rivoltini
Chemokine Receptor 7, A New Player in Regulating Apoptosis of CD8+ T Cells in Cancer Patients
Clin. Cancer Res., November 1, 2005; 11(21): 7587 - 7588.
[Full Text] [PDF]

Home page
 J. Immunol.Home page
A. A. Lugade, J. P. Moran, S. A. Gerber, R. C. Rose, J. G. Frelinger, and E. M. Lord
Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor
J. Immunol., June 15, 2005; 174(12): 7516 - 7523.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M. P. Colombo, G. Dougan, and M. Rescigno
Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells
Cancer Res., May 1, 2005; 65(9): 3920 - 3927.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. Mortarini, A. Scarito, D. Nonaka, M. Zanon, I. Bersani, E. Montaldi, E. Pennacchioli, R. Patuzzo, M. Santinami, and A. Anichini
Constitutive Expression and Costimulatory Function of LIGHT/TNFSF14 on Human Melanoma Cells and Melanoma-Derived Microvesicles
Cancer Res., April 15, 2005; 65(8): 3428 - 3436.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Kawano, C. L. Efferson, G. E. Peoples, D. Carter, N. Tsuda, J. L. Murray, and C. G. Ioannides
Sensitivity of Undifferentiated, High-TCR Density CD8+ Cells to Methylene Groups Appended to Tumor Antigen Determines Their Differentiation or Death
Cancer Res., April 1, 2005; 65(7): 2930 - 2937.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Zhou, D. Y. Jun, A. M. Thomas, X. Huang, L.-Q. Huang, J. Mautner, W. Mo, P. F. Robbins, D. M. Pardoll, and E. M. Jaffee
Diverse CD8+ T-Cell Responses to Renal Cell Carcinoma Antigens in Patients Treated with an Autologous Granulocyte-Macrophage Colony-Stimulating Factor Gene-Transduced Renal Tumor Cell Vaccine
Cancer Res., February 1, 2005; 65(3): 1079 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Sensi, G. Nicolini, M. Zanon, C. Colombo, A. Molla, I. Bersani, R. Lupetti, G. Parmiani, and A. Anichini
Immunogenicity without Immunoselection: A Mutant but Functional Antioxidant Enzyme Retained in a Human Metastatic Melanoma and Targeted by CD8+ T Cells with a Memory Phenotype
Cancer Res., January 15, 2005; 65(2): 632 - 640.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y.-J. Kim, T. M. Stringfield, Y. Chen, and H. E. Broxmeyer
Modulation of cord blood CD8+ T-cell effector differentiation by TGF-{beta}1 and 4-1BB costimulation
Blood, January 1, 2005; 105(1): 274 - 281.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Meidenbauer, A. Zippelius, M. J. Pittet, M. Laumer, S. Vogl, J. Heymann, M. Rehli, B. Seliger, S. Schwarz, F.-A. L. Gal, et al.
High Frequency of Functionally Active Melan-A-Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma
Cancer Res., September 1, 2004; 64(17): 6319 - 6326.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Di Nicola, C. Carlo-Stella, R. Mortarini, P. Baldassari, A. Guidetti, G. F. Gallino, M. Del Vecchio, F. Ravagnani, M. Magni, P. Chaplin, et al.
Boosting T Cell-Mediated Immunity to Tyrosinase by Vaccinia Virus-Transduced, CD34+-Derived Dendritic Cell Vaccination: A Phase I Trial in Metastatic Melanoma
Clin. Cancer Res., August 15, 2004; 10(16): 5381 - 5390.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Zippelius, P. Batard, V. Rubio-Godoy, G. Bioley, D. Lienard, F. Lejeune, D. Rimoldi, P. Guillaume, N. Meidenbauer, A. Mackensen, et al.
Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance
Cancer Res., April 15, 2004; 64(8): 2865 - 2873.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.